[go: up one dir, main page]

AU2585197A - Antisense approach to gene inhibition - Google Patents

Antisense approach to gene inhibition

Info

Publication number
AU2585197A
AU2585197A AU25851/97A AU2585197A AU2585197A AU 2585197 A AU2585197 A AU 2585197A AU 25851/97 A AU25851/97 A AU 25851/97A AU 2585197 A AU2585197 A AU 2585197A AU 2585197 A AU2585197 A AU 2585197A
Authority
AU
Australia
Prior art keywords
antisense approach
gene inhibition
inhibition
gene
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25851/97A
Inventor
Lawrence T. Feldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2585197A publication Critical patent/AU2585197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU25851/97A 1996-03-20 1997-03-20 Antisense approach to gene inhibition Abandoned AU2585197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1379696P 1996-03-20 1996-03-20
US60013796 1996-03-20
PCT/US1997/004519 WO1997034638A1 (en) 1996-03-20 1997-03-20 Antisense approach to gene inhibition

Publications (1)

Publication Number Publication Date
AU2585197A true AU2585197A (en) 1997-10-10

Family

ID=21761790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25851/97A Abandoned AU2585197A (en) 1996-03-20 1997-03-20 Antisense approach to gene inhibition

Country Status (2)

Country Link
AU (1) AU2585197A (en)
WO (1) WO1997034638A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053314A1 (en) * 1998-02-12 2000-11-22 McGILL UNIVERSITY Cea/nca-based differentiation cancer therapy
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
CN1375004A (en) * 1999-04-21 2002-10-16 惠氏公司 Methods and compsotions for inhibiting the function of polynucleotide sequences
KR20020097241A (en) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 Splice-region antisense composition and method
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
SI1766010T1 (en) 2004-06-28 2011-06-30 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
CA3066050A1 (en) 2008-10-24 2010-04-29 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
WO2011057350A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
MX366485B (en) 2013-03-14 2019-07-10 Sarepta Therapeutics Inc COMPOSITIONS FOR EXON JUMPING FOR THE TREATMENT OF MUSCULAR DYSTROPHY.
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
WO1997034638A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
AU9023798A (en) Mdm2-specific antisense oligonucleotides
EP0818448B8 (en) Cycloalkano-pyridine as CETP inhibitors
AU3206697A (en) Ribozyme-mediated gene replacement
AU4787697A (en) Therapeutic gene
AU6477498A (en) Scale inhibitors
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
ZA972000B (en) Inhibition of proliferation of cells.
AU5259498A (en) Antisense oligonucleotides
AU2585197A (en) Antisense approach to gene inhibition
AU9089398A (en) New plant genes
AU4173497A (en) Monocot seed gene expression system
AU6417799A (en) Matrix-remodeling genes
AU1082701A (en) Short segments of dap-kinase
AU6422798A (en) Stabilized urease inhibitor
AU2445997A (en) Telomerase inhibitors
AU2584395A (en) Antisense oligomers for inhibiting human papillomaviruses
AU5065698A (en) Improvements to gas-masks
AU5126298A (en) Inhibition of crib-biting
AU6508298A (en) Fouling inhibition
AU4700197A (en) Corrosion inhibition
AUPO060996A0 (en) Sexing gene
AU6578298A (en) Antisense inhibition of angiogenin expression
AU6487699A (en) Antisense oligomer
AU5825896A (en) Well inhibition
AU4205497A (en) Bioreactor